SWAV Shockwave Medical

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2022 Results and Participation in Upcoming Investor Conference

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2022 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, August 10, 2022, at 3:00 p.m. Eastern Time, Shockwave Medical management is scheduled for a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference, which is taking place from Monday, August 8 - Thursday, August 11, 2022 at the InterContinental Hotel in Boston, MA.

Interested parties may access live and archived webcasts of these events on the "News & Events" section of the company’s investor website at .  

To access the live second quarter 2022 earnings call via telephone, please register in advance using the link . Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call.

About Shockwave Medical, Inc.

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. To view an animation of the IVL procedure and for more information, visit .

Media Contact:

Scott Shadiow

+1.317.432.9210

 

Investor Contact:

Debbie Kaster

 



EN
25/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shockwave Medical

 PRESS RELEASE

Shockwave Medical Reports First Quarter 2024 Financial Results

Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...

 PRESS RELEASE

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-W...

Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch